TLR9 and colitis: In preclinical models, reducing luminal viral DNA attenuated TLR9 signaling and mitigated colitis, whereas exogenous CpG restored the inflammatory response and the TLR9 antagonist oligodeoxynucleotide 2088 (ODN-2088) reversed it[56,57].